Skip to main navigation Skip to search Skip to main content

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970–1999: A report from the Childhood Cancer Survivor Study

  • Duncan C. Ramsey
  • , David S. Shulman
  • , Grace C. Zhou
  • , Danielle Cameron
  • , Erik Geiger
  • , Rebecca M. Howell
  • , Kevin Krull
  • , Andrew J. Murphy
  • , Kirsten K. Ness
  • , Lucie M. Turcotte
  • , Kevin A. Raskin
  • , Deo Kumar Srivastava
  • , Yutaka Yasui
  • , Eric J. Chow
  • , Gregory T. Armstrong
  • , Brent R. Weil
  • , Steven G. Dubois
  • , Christopher B. Weldon

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Survivors of Ewing sarcoma (EWS) are at significant long-term risk of treatment- and disease-related complications. The purpose of this study was to characterize long-term outcomes in EWS survivors according to treatment regimen. Methods: Five-year survivors of EWS diagnosed between 1970 and 1999 from the Childhood Cancer Survivor Study were included. Late mortality (>5 years from diagnosis), subsequent malignant neoplasms (SMNs), and severe to fatal chronic health conditions (CHCs) by chemotherapy regimen were compared. Patients were compared to siblings via cumulative incidence and proportional hazards models. Standardized mortality ratios (SMRs) compared late mortality between survivors and the general population. Results: Survivors (N = 739) had higher all-cause (SMR, 6.16; 95% CI, 5.36–7.05), SMN-related (SMR, 9.24; 95% CI, 6.92–12.08), cardiac-related (SMR, 4.53; 95% CI, 2.81–6.93), and noncardiopulmonary health-related (SMR, 2.04; 95% CI, 1.25–3.15) mortality compared with the general population. Compared with siblings (N = 5040), survivors had an increased risk of developing CHCs (any: hazard ratio [HR], 5.49; 95% CI, 4.58–6.59; cardiovascular: HR, 4.59; 95% CI, 3.67–5.74; neurological: HR, 2.82; 95% CI, 1.72–4.63; respiratory: HR, 5.37; 95% CI, 2.76–10.5; renal: HR, 4.61; 95% CI, 2.26–9.40). Between chemotherapy groups within EWS, there were no statistically significant differences in all-cause, SMN-caused, or health-related late mortality and the risk of developing SMNs or CHCs (any, cardiovascular, neurological, or respiratory), except that the vincristine, doxorubicin, and cyclophosphamide (VDC) plus ifosfamide and etoposide (IE) group had a higher risk of renal complications (HR, 2.55; 95% CI, 1.07–11.7; 30-year incidence was 0.56% for VDC and 3.2% for VDC/IE). Conclusions: No differences in late mortality, SMNs, and most CHCs were observed between patients who received VDC versus VDC/IE. Aging EWS survivors’ elevated risk of morbidity and mortality underscores the need for lifelong survivorship care and therapies that reduce the risk for late effects.

Original languageEnglish (US)
Article numbere70504
JournalCancer
Volume132
Issue number14
DOIs
StatePublished - Jul 15 2026

Bibliographical note

Publisher Copyright:
© 2026 American Cancer Society.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Childhood Cancer Survivor Study
  • Ewing sarcoma
  • chronic disease
  • survivorship

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970–1999: A report from the Childhood Cancer Survivor Study'. Together they form a unique fingerprint.

Cite this